Merck & Co Cancer Chief Reflects on 'Foundational' Keytruda
Executive Summary
Roger Dansey, head of Merck's clinical development in oncology, tells Scrip that the Keynote clinical program for the blockbuster PD-1 inhibitor continues to hit endpoints across diseases and there is much more to come.
You may also be interested in...
Incyte Adds PD-1 Inhibitor To Its Promising IDO With MacroGenics Deal
Incyte's potential $900m licensing agreement with MacroGenics for its clinical-stage checkpoint inhibitor is considered a strong strategic move for Incyte, with the PD-1 inhibitor, MGA012, likely to become a cornerstone of its immune-oncology combination cancer therapies.
Merck's Keytruda Gets Benefit Of Doubt, Despite Failing in Head & Neck
Prior PD-1 failures after accelerated approval include Roche's Tecentriq in bladder cancer.
Finance Watch: Venture Floodgates Open With New Funds, Dozens Of Rounds
Private Company Edition: While the tough state of financing for publicly traded drug developers continues, venture capital firms and private biopharma companies revealed billions of dollars in new VC funds and start-up financings, including $100m-plus mega-rounds for Tessa, Alladapt and ImCheck.